Stryker Corporation
Change company
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
IN
US
US
US
US
US
US
US
US
US
US
US
AU
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
JP
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
BM
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
CA
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
CA
US
US
US
US
US
US
US
US
Track Stryker Corporation in real time with a live news feed covering Stryker Corporation stock news, official press releases, company announcements, and an archive of historical Stryker Corporation news. ...more
Loading news...
Loading more...
9:18 AM | Thursday | Jul 9, 2026
Sign in to download news snippet
Stryker remains a high-quality MedTech compounder despite a rare Q1 miss driven by a temporary cyber disruption. Q1 weakness was not demand-driven; full-year guidance is unchanged and end-market demand remains healthy. Current valuation reflects temporary disruption, offering a more attractive entry into SYK, though the stock is not cheap.
Read full articleNo data available for this time period.
Change the time range to see results.
Stryker remains a high-quality MedTech compounder despite a rare Q1 miss driven by a temporary cyber disruption. Q1 weakness was not demand-driven; full-year guidance is unchanged and end-market demand remains healthy. Current valuation reflects temporary disruption, offering a more attractive entry into SYK, though the stock is not cheap.
Read full article
Stryker remains a high-quality MedTech compounder despite a rare Q1 miss driven by a temporary cyber disruption. Q1 weakness was not demand-driven; full-year guidance is unchanged and end-market demand remains healthy. Current valuation reflects temporary disruption, offering a more attractive entry into SYK, though the stock is not cheap.
Read full article
Investors looking for stocks in the Medical - Products sector might want to consider either ICU Medical (ICUI) or Stryker (SYK). But which of these two stocks offers value investors a better bang for their buck right now?
Read full article
Stryker Corporation offers a compelling medtech investment, benefiting from robust industry growth and an innovation-led strategy. SYK trades at a 13% discount to fair value, with a forward P/E of 20.1 versus a 10-year average of 25.6. Consensus expects SYK's adjusted diluted EPS to compound at 11.
2% annually through 2028, supporting high single-digit dividend growth.
Markets have become more volatile as investors debate whether big tech companies are getting enough return on their AI spending. The S&P 500 momentum index has outperformed the wider market by more than 70% since 2024, close to levels seen during the 1990s dot-com era.
Read full article
Stryker is a Dividend Aristocrat with 32 years of increases, robust cash flow, and a strong M&A-driven growth strategy. SYK's Q1 2026 results were impacted by a cybersecurity incident, but management maintained full-year guidance and expects normalization. The stock trades at ~21x 2026E EPS, below its 5-year average, suggesting undervaluation despite recent share price declines.
Read full article
Stryker (NYSE:SYK | SYK Price Prediction) and Intuitive Surgical (NASDAQ:ISRG) both closed the books on Q1 2026 with sharply different results.
Read full article
Portage, Michigan, July 01, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK) will host a webcast at 4:30 p.m. (Eastern time) on Thursday, July 30, 2026, to discuss its second quarter 2026 financial results.
Read full article
On June 30, 2026, Stryker Corp (SYK) shares fell 4.7% to a current price of $314.84. This decline comes in a challenging year where the stock has seen a year-to
Read full article
Stryker (SYK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Read full article
PORTAGE, Mich., June 24, 2026 /PRNewswire/ -- Stryker (NYSE: SYK), a global leader in medical technologies, today announced a new partnership with Major Champion and globally recognized golfer Shane Lowry at the Travelers Championship in Cromwell, Connecticut, naming him a sponsored brand ambassador for its Joint Replacement division.
Read full article
No data available for this time period.
Change the time range to see results.